CHEMOMAB THERAPEUTICS LTD's ticker is CMMB and the CUSIP is 16385C104. A total of 16 filers reported holding CHEMOMAB THERAPEUTICS LTD in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $132 | -98.9% | 100 | -98.7% | 0.00% | – |
| Q1 2023 | $12,402 | -41.3% | 7,800 | +18.2% | 0.00% | – |
| Q4 2022 | $21,120 | +40.8% | 6,600 | +6.5% | 0.00% | – |
| Q3 2022 | $15,000 | -28.6% | 6,200 | +10.8% | 0.00% | – |
| Q2 2022 | $21,000 | -73.8% | 5,595 | -51.9% | 0.00% | – |
| Q4 2021 | $80,000 | +7900.0% | 11,643 | +12155.8% | 0.00% | – |
| Q3 2021 | $1,000 | -66.7% | 95 | -41.7% | 0.00% | – |
| Q2 2021 | $3,000 | -70.0% | 163 | -51.2% | 0.00% | – |
| Q1 2021 | $10,000 | – | 334 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,578,174 | $12,375,000 | 0.20% |
| Ikarian Capital, LLC | 268,104 | $1,292,000 | 0.17% |
| Cormorant Asset Management, LP | 288,168 | $1,383,000 | 0.11% |
| BOOTHBAY FUND MANAGEMENT, LLC | 41,298 | $198,000 | 0.01% |
| MEITAV INVESTMENT HOUSE LTD | 35,024 | $167,000 | 0.00% |
| Newbridge Financial Services Group, Inc. | 1,100 | $5,000 | 0.00% |
| ENVESTNET ASSET MANAGEMENT INC | 10,807 | $52,000 | 0.00% |
| JPMORGAN CHASE & CO | 753 | $4,000 | 0.00% |
| Renaissance Technologies | 27,960 | $134,000 | 0.00% |
| ARK Investment Management | 792 | $4,000 | 0.00% |